Holistic stroke awareness will mitigate rising disease burden in India: GlobalData | The Financial Express

Holistic stroke awareness will mitigate rising disease burden in India: GlobalData

The data analytics company claims that the current treatment options for stroke in India vary with the severity of the situation.

Holistic stroke awareness will mitigate rising disease burden in India: GlobalData
Unfortunately, many people think that forgetfulness is the first sign of Alzheimer’s disease. (Image Credit: Pixabay)

GlobalData on Wednesday said that better awareness of the warning signs and risk factors of Brain stroke or Acute Ischemic Stroke (AIS) at all levels of care will not only help save lives but also reduces the disease burden. According to the company, brain stroke is the fourth leading cause of death, as well as the fifth leading cause of disability in India. Moreover, the lack of disease awareness is one of the primary reasons behind the increasing incidence of the disease.

According to ‘GlobalData’s Pharmaceutical Intelligence Center’, the incidence of stroke in India ranges between 104 and 105/100,000 people per year, with an expected increase in diagnosed incident cases from 6.2 million in 2022 to 6.7 million in 2027, at an annual growth rate (AGR) of 1.7 percent.

Recently, Boehringer Ingelheim (BI) has conducted the first-ever consumer survey on brain stroke – “The State of Stroke: A Survey on Awareness About Stroke In Urban India” on the occasion of World Brain Day.

The aim of this survey was to bring forth the prime factor responsible for the magnitude of the disease burden, i.e., lack of awareness around brain stroke in the country. The survey findings, based on 4,742 respondents across 12 cities in India, revealed that only 22 percent of them were aware of brain stroke and its risk factors, with awareness level dropping to a meager 10 percent with respect to stroke-related treatment options. Actilyse and Pradaxa are the two BI drugs used for stroke treatment and management in India.

“Along with an aging population, susceptibility to cardio-metabolic dysfunction due to a more vulnerable race and ethnicity, and other risk factors like hypertension and type 2 diabetes, which are working in cohort to increase the stroke prevalence and incidence, limited awareness among the population surrounding this disease are adding on to the burden,” Atulana Dey, Pharma Analyst at GlobalData, said in a statement on Wednesday.

The data analytics company claims that the current treatment options for stroke in India vary with the severity of the situation. Intravenous administration of recombinant tissue plasminogen activator (TPA) within 4.5 hours of the stroke episode is the gold standard of first-line treatment, it stated.

According to the company, due to the increased stress, anxiety and unhealthy food lifestyle that has developed rapidly over the last decade, age group of 18–50 is equally prone to this debilitating condition as is the aging population.

“The escalating stroke incidence calls for the government and key companies to join forces and act on the unmet need of creating an enhanced understanding of stroke symptoms, risk factors, treatment options and preventative measures. Improved knowledge of the disease will not only help patients and families identify the condition, but a prompt response within a few hours of identification can also help save lives by limiting the overall long-term physical and neurological damage,” Dey said on Wednesday.

ALSO READ | AstraZeneca likely to see substantial Evusheld uptake in Japan: GlobalData

Get live Share Market updates and latest India News and business news on Financial Express. Download Financial Express App for latest business news.